High-affinity immunoglobulin gamma Fc receptor I co-engaged with High-affinity immunoglobulin epsilon receptor I via Fel d 1-specific immunoglobulin E (FcγRI-FcεRI-Fel d 1 complex)

The target refers to a therapeutic molecular complex formed by the co-engagement of the high-affinity IgG receptor (FcγRI/CD64) and the high-affinity IgE receptor (FcεRI) on the surface of immune cells, specifically mediated by the cat allergen Fel d 1 and Fel d 1-specific IgE. This co-engagement is a specialized strategy designed to modulate allergic immune responses by exploiting the signaling pathways of FcγRI to alter the outcome of allergen recognition. Unlike traditional inhibitory strategies that target FcγRIIb to block mast cell degranulation, this approach focuses on antigen-presenting cells like dendritic cells to redirect T-cell differentiation. Experimental fusion proteins, such as H22-Fel d 1, facilitate this interaction by binding directly to FcγRI while presenting the Fel d 1 allergen to IgE already bound to FcεRI. This process has been shown to induce a regulatory immune profile characterized by increased IL-10 production and modulation of the TSLP receptor pathway, potentially leading to long-term immune tolerance in cat-allergic individuals.

Other names

CD64-FcεRI-Fel d 1 complexH22-Fel d 1 targeted complexReceptor-targeted Fel d 1 complexFcγRI-FcεRI co-engagement

Simultaneous ligation of FcγRI and IgE-bound FcεRI on dendritic cells to redirect allergen processing and induce a tolerogenic T-cell response.